Sobre nósBem vindo à BioCellTis Bioengenharia Ltda. Uma empresa de engenharia biomédica.
ArtSkin™ is BioCellTis’ artificial skin platform. We developed a 3D-reconstructed in vitro human skin for the testing of chemicals, pharmaceuticals and skin-care products. In addition, temporary and permanent skin scaffolds that not only are completely absorbable, but also used as a permanent replacement based on concepts of regenerative medicine. ArtSkin™ applications:
– Human skin reconstruction
– Wound healing
– Skin regeneration
– Skin maintenance
– Skin replacement
– Sensory membrane
BioCellTis intends to meet the demands of both the animal and human breeding markets by offering the 3D CellFate® IVF matrix, that should increase the percentage of success in the process of in vitro fertilisation and ensure the maintenance of the genetic quality of embryos.
3D CellFate® IVF matrix mimics the ideal microenvironment for the maturation of oocyte to blastocysts, avoiding alterations in the expression of adhesion proteins that are present in the cell membrane. Ready to use and easy to handle, 3D CellFate® IVF suit all sizes of plates used in laboratories for fertilisation, and it can also be customized for specific purposes. The product has unique transparency which allows you to view cells at any stage of the procedure.
BioCellTis’ bioengineered in vito platforms aim to recreate the molecular and phenotypical mechanisms of cancer progression by developing reproducible models. Currently our platform TumorMatrix™ can mimic resistance to cell death, proliferation processes, invasiveness and metastase, immortality and angiogenesis.
Vasculogenic mimicry as observed in human melanoma cells cultured on the TumorMatrix™ platform.
Absence of vasculogenic mimicry as observed in human melanoma cells cultured on another company’s platform.
Through our TumorMatrix™ platform, we intend to meet the demands of the pharmaceutical industry in the discovery of drugs capable of blocking tumor progression, as well as the provision of services geared to the personalized treatment of cancer.
This post is also available in: Portuguese (Brazil)